Researchers found that patients being treated with statins at the time of surgery for renal cell carcinoma had improved overall survival and disease-specific survival.
Interim results from a global, randomized phase II study in people with previously treated non-small cell lung cancer showed that the immunotherapy MPDL3280A doubled the overall survival (HR=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy.
Updated long-term survival results from IMAGE 1, a phase II clinical trial evaluating a combination of IMM-101 and gemcitabine as first-line treatment for advanced pancreatic cancer, found that, in patients with metastatic disease, IMM-101 was associated with improving the probability of survival at 12 months to 24 percent, compared to 11.5 percent in patients receiving gemcitabine alone.
CHICAGO—The American Society of Clinical Oncology announced June 1 that it will move forward with its first-ever clinical trial, a study designed to offer patients with advanced cancer access to molecularly-targeted cancer drugs and to collect data on clinical outcomes to learn the best uses of these drugs outside of FDA-approved indications.
CHICAGO—NCI's long-planned, large scale precision medicine trial will open to patient enrollment in July, investigators announced June 1 at the annual meeting of the American Society of Clinical Oncology.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Researchers at NCI found that measurement of circulating tumor DNA in blood can be used to detect disease recurrence in patients with diffuse large B-cell lymphoma.
Data from an on-going phase II trial of the AE37 breast cancer vaccine correlated local immune response to a reduction in relapse.
FDA approved a label update for Zytiga (abiraterone acetate) plus prednisone to include overall survival results in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
Astellas Pharma Inc. and Medivation Inc. presented an updated overall survival analysis from the placebo-controlled phase III trial of Xtandi in chemotherapy-naive metastatic CRPC.
